CVRX
CVRx, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.43
+1.79%Oct 22, 2026, 20:30 UTC
CVRx, Inc. announced that it plans to release its third-quarter 2026 financial and operating results after market close on November 5, 2026, and host a conference call at 4:30 p.m. Eastern Time that day.
Source:Sep 29, 2026, 20:30 UTC
CVRx announced the schedule of scientific presentations featuring its Barostim neuromodulation therapy at the Heart Failure Society of America Annual Scientific Meeting 2026.
Source:Sep 21, 2026, 20:17 UTC
CVRx, Inc. appointed John Landry as Chief Financial Officer effective October 12, 2026, succeeding Jared Oasheim, who resigned.
Sep 1, 2026, 21:48 UTC
Pomerantz LLP announced an investigation into CVRx, Inc. for potential securities fraud or unlawful business practices on behalf of investors.
Source:Aug 24, 2026, 12:30 UTC
Jorey Chernett, beneficial owner of more than 5.5% of CVRx's outstanding shares, delivered a letter to the CVRx Board urging it to launch an immediate process to sell the company to a strategic acquirer.
Source:Aug 24, 2026, 12:30 UTC
CVRx announced that Devoted Health issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026, covering approximately 466,000 members across 29 states.
Source:Aug 13, 2026, 07:03 UTC
CVRx announced the launch of the BENEFIT-HF post-market clinical trial for its Barostim therapy.
Source:Aug 11, 2026, 00:00 UTC
CVRx, Inc. terminated Robert John as Chief Revenue Officer, effective August 10, 2026, and appointed Paul Verrastro as Interim Head of Sales, effective August 11, 2026.
Aug 7, 2026, 15:56 UTC
Johnson Fistel, PLLP announced an investigation into CVRx, Inc. and certain executive officers for potential violations of state or federal securities laws related to investor losses.
Source:Aug 6, 2026, 20:05 UTC
CVRx, Inc. announced its financial and operating results for the second quarter of 2026 on August 6, 2026.
Jun 9, 2026, 00:00 UTC
Jared Oasheim resigned as Chief Financial Officer of CVRx, Inc., effective June 8, 2026, with transition support and consulting arrangements through February 2027.
Source: